Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
27.5 USD | +1.23% | -3.97% | -34.49% |
04-20 | Immunovant Insider Sold Shares Worth $990,269, According to a Recent SEC Filing | MT |
04-20 | Immunovant Insider Sold Shares Worth $293,923, According to a Recent SEC Filing | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.49% | 3.95B | |
+1.53% | 42.75B | |
+47.70% | 41.61B | |
+12.02% | 41.34B | |
-8.83% | 26.59B | |
+6.90% | 25.49B | |
-23.06% | 18.12B | |
+30.30% | 12.24B | |
-2.33% | 11.76B | |
+8.61% | 11B |
- Stock Market
- Equities
- IMVT Stock
- News Immunovant, Inc.
- Immunovant Gets FDA Nod to Begin Phase 3 Study of Batoclimab in Treating Myasthenia Gravis; Shares Rise